Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Gastric Cancer Market, by Route of Administration
1.4.2 Global Gastric Cancer Market, by Treatment Type
1.4.3 Global Gastric Cancer Market, by Disease Type
1.4.4 Global Gastric Cancer Market, by Distribution Channel
1.4.5 Global Gastric Cancer Market, by Drug Class
1.4.6 Global Gastric Cancer Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Approvals & Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. Global Gastric Cancer Market by Route of Administration
4.1 Global Injectable Market by Region
4.2 Global Oral Market by Region
Chapter 5. Global Gastric Cancer Market by Treatment Type
5.1 Global Chemotherapy Market by Region
5.2 Global Targeted Therapy Market by Region
5.3 Global Immunotherapy Market by Region
5.4 Global Radiation Therapy & Surgery Market by Region
Chapter 6. Global Gastric Cancer Market by Disease Type
6.1 Global Adenocarcinoma Market by Region
6.2 Global Carcinoid Tumor Market by Region
6.3 Global Gastrointestinal Stromal Tumor Market by Region
6.4 Global Lymphoma Market by Region
6.5 Global Others Market by Region
Chapter 7. Global Gastric Cancer Market by Distribution Channel
7.1 Global Specialty & Retail Pharmacies Market by Region
7.2 Global Hospital Pharmacies Market by Region
7.3 Global Others Market by Region
Chapter 8. Global Gastric Cancer Market by Drug Class
8.1 Global PD-1/PD-L1 Inhibitors Market by Region
8.2 Global HER2 Antagonists Market by Region
8.3 Global VEGFR2 Antagonists Market by Region
8.4 Global Others Market by Region
Chapter 9. Global Gastric Cancer Market by Region
9.1 North America Gastric Cancer Market
9.1.1 North America Gastric Cancer Market by Route of Administration
9.1.1.1 North America Injectable Market by Country
9.1.1.2 North America Oral Market by Country
9.1.2 North America Gastric Cancer Market by Treatment Type
9.1.2.1 North America Chemotherapy Market by Country
9.1.2.2 North America Targeted Therapy Market by Country
9.1.2.3 North America Immunotherapy Market by Country
9.1.2.4 North America Radiation Therapy & Surgery Market by Country
9.1.3 North America Gastric Cancer Market by Disease Type
9.1.3.1 North America Adenocarcinoma Market by Country
9.1.3.2 North America Carcinoid Tumor Market by Country
9.1.3.3 North America Gastrointestinal Stromal Tumor Market by Country
9.1.3.4 North America Lymphoma Market by Country
9.1.3.5 North America Others Market by Country
9.1.4 North America Gastric Cancer Market by Distribution Channel
9.1.4.1 North America Specialty & Retail Pharmacies Market by Country
9.1.4.2 North America Hospital Pharmacies Market by Country
9.1.4.3 North America Others Market by Country
9.1.5 North America Gastric Cancer Market by Drug Class
9.1.5.1 North America PD-1/PD-L1 Inhibitors Market by Country
9.1.5.2 North America HER2 Antagonists Market by Country
9.1.5.3 North America VEGFR2 Antagonists Market by Country
9.1.5.4 North America Others Market by Country
9.1.6 North America Gastric Cancer Market by Country
9.1.6.1 US Gastric Cancer Market
9.1.6.1.1 US Gastric Cancer Market by Route of Administration
9.1.6.1.2 US Gastric Cancer Market by Treatment Type
9.1.6.1.3 US Gastric Cancer Market by Disease Type
9.1.6.1.4 US Gastric Cancer Market by Distribution Channel
9.1.6.1.5 US Gastric Cancer Market by Drug Class
9.1.6.2 Canada Gastric Cancer Market
9.1.6.2.1 Canada Gastric Cancer Market by Route of Administration
9.1.6.2.2 Canada Gastric Cancer Market by Treatment Type
9.1.6.2.3 Canada Gastric Cancer Market by Disease Type
9.1.6.2.4 Canada Gastric Cancer Market by Distribution Channel
9.1.6.2.5 Canada Gastric Cancer Market by Drug Class
9.1.6.3 Mexico Gastric Cancer Market
9.1.6.3.1 Mexico Gastric Cancer Market by Route of Administration
9.1.6.3.2 Mexico Gastric Cancer Market by Treatment Type
9.1.6.3.3 Mexico Gastric Cancer Market by Disease Type
9.1.6.3.4 Mexico Gastric Cancer Market by Distribution Channel
9.1.6.3.5 Mexico Gastric Cancer Market by Drug Class
9.1.6.4 Rest of North America Gastric Cancer Market
9.1.6.4.1 Rest of North America Gastric Cancer Market by Route of Administration
9.1.6.4.2 Rest of North America Gastric Cancer Market by Treatment Type
9.1.6.4.3 Rest of North America Gastric Cancer Market by Disease Type
9.1.6.4.4 Rest of North America Gastric Cancer Market by Distribution Channel
9.1.6.4.5 Rest of North America Gastric Cancer Market by Drug Class
9.2 Europe Gastric Cancer Market
9.2.1 Europe Gastric Cancer Market by Route of Administration
9.2.1.1 Europe Injectable Market by Country
9.2.1.2 Europe Oral Market by Country
9.2.2 Europe Gastric Cancer Market by Treatment Type
9.2.2.1 Europe Chemotherapy Market by Country
9.2.2.2 Europe Targeted Therapy Market by Country
9.2.2.3 Europe Immunotherapy Market by Country
9.2.2.4 Europe Radiation Therapy & Surgery Market by Country
9.2.3 Europe Gastric Cancer Market by Disease Type
9.2.3.1 Europe Adenocarcinoma Market by Country
9.2.3.2 Europe Carcinoid Tumor Market by Country
9.2.3.3 Europe Gastrointestinal Stromal Tumor Market by Country
9.2.3.4 Europe Lymphoma Market by Country
9.2.3.5 Europe Others Market by Country
9.2.4 Europe Gastric Cancer Market by Distribution Channel
9.2.4.1 Europe Specialty & Retail Pharmacies Market by Country
9.2.4.2 Europe Hospital Pharmacies Market by Country
9.2.4.3 Europe Others Market by Country
9.2.5 Europe Gastric Cancer Market by Drug Class
9.2.5.1 Europe PD-1/PD-L1 Inhibitors Market by Country
9.2.5.2 Europe HER2 Antagonists Market by Country
9.2.5.3 Europe VEGFR2 Antagonists Market by Country
9.2.5.4 Europe Others Market by Country
9.2.6 Europe Gastric Cancer Market by Country
9.2.6.1 Germany Gastric Cancer Market
9.2.6.1.1 Germany Gastric Cancer Market by Route of Administration
9.2.6.1.2 Germany Gastric Cancer Market by Treatment Type
9.2.6.1.3 Germany Gastric Cancer Market by Disease Type
9.2.6.1.4 Germany Gastric Cancer Market by Distribution Channel
9.2.6.1.5 Germany Gastric Cancer Market by Drug Class
9.2.6.2 UK Gastric Cancer Market
9.2.6.2.1 UK Gastric Cancer Market by Route of Administration
9.2.6.2.2 UK Gastric Cancer Market by Treatment Type
9.2.6.2.3 UK Gastric Cancer Market by Disease Type
9.2.6.2.4 UK Gastric Cancer Market by Distribution Channel
9.2.6.2.5 UK Gastric Cancer Market by Drug Class
9.2.6.3 France Gastric Cancer Market
9.2.6.3.1 France Gastric Cancer Market by Route of Administration
9.2.6.3.2 France Gastric Cancer Market by Treatment Type
9.2.6.3.3 France Gastric Cancer Market by Disease Type
9.2.6.3.4 France Gastric Cancer Market by Distribution Channel
9.2.6.3.5 France Gastric Cancer Market by Drug Class
9.2.6.4 Russia Gastric Cancer Market
9.2.6.4.1 Russia Gastric Cancer Market by Route of Administration
9.2.6.4.2 Russia Gastric Cancer Market by Treatment Type
9.2.6.4.3 Russia Gastric Cancer Market by Disease Type
9.2.6.4.4 Russia Gastric Cancer Market by Distribution Channel
9.2.6.4.5 Russia Gastric Cancer Market by Drug Class
9.2.6.5 Spain Gastric Cancer Market
9.2.6.5.1 Spain Gastric Cancer Market by Route of Administration
9.2.6.5.2 Spain Gastric Cancer Market by Treatment Type
9.2.6.5.3 Spain Gastric Cancer Market by Disease Type
9.2.6.5.4 Spain Gastric Cancer Market by Distribution Channel
9.2.6.5.5 Spain Gastric Cancer Market by Drug Class
9.2.6.6 Italy Gastric Cancer Market
9.2.6.6.1 Italy Gastric Cancer Market by Route of Administration
9.2.6.6.2 Italy Gastric Cancer Market by Treatment Type
9.2.6.6.3 Italy Gastric Cancer Market by Disease Type
9.2.6.6.4 Italy Gastric Cancer Market by Distribution Channel
9.2.6.6.5 Italy Gastric Cancer Market by Drug Class
9.2.6.7 Rest of Europe Gastric Cancer Market
9.2.6.7.1 Rest of Europe Gastric Cancer Market by Route of Administration
9.2.6.7.2 Rest of Europe Gastric Cancer Market by Treatment Type
9.2.6.7.3 Rest of Europe Gastric Cancer Market by Disease Type
9.2.6.7.4 Rest of Europe Gastric Cancer Market by Distribution Channel
9.2.6.7.5 Rest of Europe Gastric Cancer Market by Drug Class
9.3 Asia Pacific Gastric Cancer Market
9.3.1 Asia Pacific Gastric Cancer Market by Route of Administration
9.3.1.1 Asia Pacific Injectable Market by Country
9.3.1.2 Asia Pacific Oral Market by Country
9.3.2 Asia Pacific Gastric Cancer Market by Treatment Type
9.3.2.1 Asia Pacific Chemotherapy Market by Country
9.3.2.2 Asia Pacific Targeted Therapy Market by Country
9.3.2.3 Asia Pacific Immunotherapy Market by Country
9.3.2.4 Asia Pacific Radiation Therapy & Surgery Market by Country
9.3.3 Asia Pacific Gastric Cancer Market by Disease Type
9.3.3.1 Asia Pacific Adenocarcinoma Market by Country
9.3.3.2 Asia Pacific Carcinoid Tumor Market by Country
9.3.3.3 Asia Pacific Gastrointestinal Stromal Tumor Market by Country
9.3.3.4 Asia Pacific Lymphoma Market by Country
9.3.3.5 Asia Pacific Others Market by Country
9.3.4 Asia Pacific Gastric Cancer Market by Distribution Channel
9.3.4.1 Asia Pacific Specialty & Retail Pharmacies Market by Country
9.3.4.2 Asia Pacific Hospital Pharmacies Market by Country
9.3.4.3 Asia Pacific Others Market by Country
9.3.5 Asia Pacific Gastric Cancer Market by Drug Class
9.3.5.1 Asia Pacific PD-1/PD-L1 Inhibitors Market by Country
9.3.5.2 Asia Pacific HER2 Antagonists Market by Country
9.3.5.3 Asia Pacific VEGFR2 Antagonists Market by Country
9.3.5.4 Asia Pacific Others Market by Country
9.3.6 Asia Pacific Gastric Cancer Market by Country
9.3.6.1 China Gastric Cancer Market
9.3.6.1.1 China Gastric Cancer Market by Route of Administration
9.3.6.1.2 China Gastric Cancer Market by Treatment Type
9.3.6.1.3 China Gastric Cancer Market by Disease Type
9.3.6.1.4 China Gastric Cancer Market by Distribution Channel
9.3.6.1.5 China Gastric Cancer Market by Drug Class
9.3.6.2 Japan Gastric Cancer Market
9.3.6.2.1 Japan Gastric Cancer Market by Route of Administration
9.3.6.2.2 Japan Gastric Cancer Market by Treatment Type
9.3.6.2.3 Japan Gastric Cancer Market by Disease Type
9.3.6.2.4 Japan Gastric Cancer Market by Distribution Channel
9.3.6.2.5 Japan Gastric Cancer Market by Drug Class
9.3.6.3 India Gastric Cancer Market
9.3.6.3.1 India Gastric Cancer Market by Route of Administration
9.3.6.3.2 India Gastric Cancer Market by Treatment Type
9.3.6.3.3 India Gastric Cancer Market by Disease Type
9.3.6.3.4 India Gastric Cancer Market by Distribution Channel
9.3.6.3.5 India Gastric Cancer Market by Drug Class
9.3.6.4 South Korea Gastric Cancer Market
9.3.6.4.1 South Korea Gastric Cancer Market by Route of Administration
9.3.6.4.2 South Korea Gastric Cancer Market by Treatment Type
9.3.6.4.3 South Korea Gastric Cancer Market by Disease Type
9.3.6.4.4 South Korea Gastric Cancer Market by Distribution Channel
9.3.6.4.5 South Korea Gastric Cancer Market by Drug Class
9.3.6.5 Singapore Gastric Cancer Market
9.3.6.5.1 Singapore Gastric Cancer Market by Route of Administration
9.3.6.5.2 Singapore Gastric Cancer Market by Treatment Type
9.3.6.5.3 Singapore Gastric Cancer Market by Disease Type
9.3.6.5.4 Singapore Gastric Cancer Market by Distribution Channel
9.3.6.5.5 Singapore Gastric Cancer Market by Drug Class
9.3.6.6 Malaysia Gastric Cancer Market
9.3.6.6.1 Malaysia Gastric Cancer Market by Route of Administration
9.3.6.6.2 Malaysia Gastric Cancer Market by Treatment Type
9.3.6.6.3 Malaysia Gastric Cancer Market by Disease Type
9.3.6.6.4 Malaysia Gastric Cancer Market by Distribution Channel
9.3.6.6.5 Malaysia Gastric Cancer Market by Drug Class
9.3.6.7 Rest of Asia Pacific Gastric Cancer Market
9.3.6.7.1 Rest of Asia Pacific Gastric Cancer Market by Route of Administration
9.3.6.7.2 Rest of Asia Pacific Gastric Cancer Market by Treatment Type
9.3.6.7.3 Rest of Asia Pacific Gastric Cancer Market by Disease Type
9.3.6.7.4 Rest of Asia Pacific Gastric Cancer Market by Distribution Channel
9.3.6.7.5 Rest of Asia Pacific Gastric Cancer Market by Drug Class
9.4 LAMEA Gastric Cancer Market
9.4.1 LAMEA Gastric Cancer Market by Route of Administration
9.4.1.1 LAMEA Injectable Market by Country
9.4.1.2 LAMEA Oral Market by Country
9.4.2 LAMEA Gastric Cancer Market by Treatment Type
9.4.2.1 LAMEA Chemotherapy Market by Country
9.4.2.2 LAMEA Targeted Therapy Market by Country
9.4.2.3 LAMEA Immunotherapy Market by Country
9.4.2.4 LAMEA Radiation Therapy & Surgery Market by Country
9.4.3 LAMEA Gastric Cancer Market by Disease Type
9.4.3.1 LAMEA Adenocarcinoma Market by Country
9.4.3.2 LAMEA Carcinoid Tumor Market by Country
9.4.3.3 LAMEA Gastrointestinal Stromal Tumor Market by Country
9.4.3.4 LAMEA Lymphoma Market by Country
9.4.3.5 LAMEA Others Market by Country
9.4.4 LAMEA Gastric Cancer Market by Distribution Channel
9.4.4.1 LAMEA Specialty & Retail Pharmacies Market by Country
9.4.4.2 LAMEA Hospital Pharmacies Market by Country
9.4.4.3 LAMEA Others Market by Country
9.4.5 LAMEA Gastric Cancer Market by Drug Class
9.4.5.1 LAMEA PD-1/PD-L1 Inhibitors Market by Country
9.4.5.2 LAMEA HER2 Antagonists Market by Country
9.4.5.3 LAMEA VEGFR2 Antagonists Market by Country
9.4.5.4 LAMEA Others Market by Country
9.4.6 LAMEA Gastric Cancer Market by Country
9.4.6.1 Brazil Gastric Cancer Market
9.4.6.1.1 Brazil Gastric Cancer Market by Route of Administration
9.4.6.1.2 Brazil Gastric Cancer Market by Treatment Type
9.4.6.1.3 Brazil Gastric Cancer Market by Disease Type
9.4.6.1.4 Brazil Gastric Cancer Market by Distribution Channel
9.4.6.1.5 Brazil Gastric Cancer Market by Drug Class
9.4.6.2 Argentina Gastric Cancer Market
9.4.6.2.1 Argentina Gastric Cancer Market by Route of Administration
9.4.6.2.2 Argentina Gastric Cancer Market by Treatment Type
9.4.6.2.3 Argentina Gastric Cancer Market by Disease Type
9.4.6.2.4 Argentina Gastric Cancer Market by Distribution Channel
9.4.6.2.5 Argentina Gastric Cancer Market by Drug Class
9.4.6.3 UAE Gastric Cancer Market
9.4.6.3.1 UAE Gastric Cancer Market by Route of Administration
9.4.6.3.2 UAE Gastric Cancer Market by Treatment Type
9.4.6.3.3 UAE Gastric Cancer Market by Disease Type
9.4.6.3.4 UAE Gastric Cancer Market by Distribution Channel
9.4.6.3.5 UAE Gastric Cancer Market by Drug Class
9.4.6.4 Saudi Arabia Gastric Cancer Market
9.4.6.4.1 Saudi Arabia Gastric Cancer Market by Route of Administration
9.4.6.4.2 Saudi Arabia Gastric Cancer Market by Treatment Type
9.4.6.4.3 Saudi Arabia Gastric Cancer Market by Disease Type
9.4.6.4.4 Saudi Arabia Gastric Cancer Market by Distribution Channel
9.4.6.4.5 Saudi Arabia Gastric Cancer Market by Drug Class
9.4.6.5 South Africa Gastric Cancer Market
9.4.6.5.1 South Africa Gastric Cancer Market by Route of Administration
9.4.6.5.2 South Africa Gastric Cancer Market by Treatment Type
9.4.6.5.3 South Africa Gastric Cancer Market by Disease Type
9.4.6.5.4 South Africa Gastric Cancer Market by Distribution Channel
9.4.6.5.5 South Africa Gastric Cancer Market by Drug Class
9.4.6.6 Nigeria Gastric Cancer Market
9.4.6.6.1 Nigeria Gastric Cancer Market by Route of Administration
9.4.6.6.2 Nigeria Gastric Cancer Market by Treatment Type
9.4.6.6.3 Nigeria Gastric Cancer Market by Disease Type
9.4.6.6.4 Nigeria Gastric Cancer Market by Distribution Channel
9.4.6.6.5 Nigeria Gastric Cancer Market by Drug Class
9.4.6.7 Rest of LAMEA Gastric Cancer Market
9.4.6.7.1 Rest of LAMEA Gastric Cancer Market by Route of Administration
9.4.6.7.2 Rest of LAMEA Gastric Cancer Market by Treatment Type
9.4.6.7.3 Rest of LAMEA Gastric Cancer Market by Disease Type
9.4.6.7.4 Rest of LAMEA Gastric Cancer Market by Distribution Channel
9.4.6.7.5 Rest of LAMEA Gastric Cancer Market by Drug Class
Chapter 10. Company Profiles
10.1 Novartis AG
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expense
10.1.5 Recent strategies and developments:
10.1.5.1 Partnerships, Collaborations, and Agreements:
10.2 Pfizer, Inc.
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional & Segmental Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Partnerships, Collaborations, and Agreements:
10.3 Viatris, Inc. (Mylan N.V.)
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Segmental Analysis
10.3.4 Research & Development Expense
10.3.5 Recent strategies and developments:
10.3.5.1 Product Launches and Product Expansions:
10.3.5.2 Approvals & Trials:
10.4 F. Hoffmann-La Roche Ltd.
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental and Regional Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Partnerships, Collaborations, and Agreements:
10.4.5.2 Product Launches and Product Expansions:
10.5 Eli Lilly And Company
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Regional Analysis
10.5.4 Research & Development Expenses
10.5.5 Recent strategies and developments:
10.5.5.1 Approvals & Trials:
10.5.5.2 Partnerships, Collaborations, and Agreements:
10.6 Merck & Co., Inc.
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental and Regional Analysis
10.6.4 Research & Development Expenses
10.6.5 Recent strategies and developments:
10.6.5.1 Partnerships, Collaborations, and Agreements:
10.7 Teva Pharmaceutical Industries Ltd.
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Regional Analysis
10.7.4 Research & Development Expenses
10.7.5 Recent strategies and developments:
10.7.5.1 Product Launches and Product Expansions:
10.7.5.2 Approvals & Trials:
10.7.5.3 Partnerships, Collaborations, and Agreements:
10.8 Bristol Myers Squibb Company
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Regional Analysis
10.8.4 Research & Development Expenses
10.8.5 Recent strategies and developments:
10.8.5.1 Partnerships, Collaborations, and Agreements:
10.8.5.2 Approvals & Trials:
10.9 Celltrion Healthcare Co., Ltd.
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Recent strategies and developments:
10.9.3.1 Partnerships, Collaborations, and Agreements:
10.10. Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.)
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Segmental and Regional Analysis
10.10.4 Research & Development Expenses
10.10.5 Recent strategies and developments:
10.10.5.1 Approvals & Trials:
10.10.5.2 Product Launches and Product Expansions:
Unique Offerings 
